Clinical Trial Update: A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Hetrombopag Olamine Tablets for chemotherapy-induced thrombocytopenia in solid tumour patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia
• Solid Tumors

Drugs mentioned

• Hetrombopag Olamine Tablets (hetrombopag olamine)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Chemotherapy-Induced Thrombocytopenia | Phase 3 | Status: WITHDRAWN